Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combination Therapy with Luspatercept and the Ferroportin Inhibitor Vamifeport Is Superior to Either Drug Alone in Improving Anemia and Reducing Myeloid Skewing in MDS

Ada Antypiuk, Steven Vance, Franz Dürrenberger, Vania Manolova, Francesca Vinchi

Blood (2023) 142 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2023-190095

Published: 2023

Journal Articles

Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model

Ada Antypiuk, Alberto Martinez, Ute Schaeper, Uwe Platzbecker, Francesca Vinchi

Blood (2023) 142 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2023-189794

Published: 2023

Journal Articles

Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease

Richa Sharma, Ada Antypiuk, S. Zebulon Vance, Deepa Manwani, Quentinn Pearce, James E. Cox, Xiuli An, Karina Yazdanbakhsh, Francesca Vinchi

Blood (2023) 141 (25): 3091–3108.

https://doi.org/10.1182/blood.2022018026

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic Iron Overload Aggravates and Pharmacological Iron Restriction Improves MDS Pathophysiology in a Preclinical Mouse Model

S. Zebulon Vance, Ada Antypiuk, Richa Sharma, Franz Dürrenberger, Vania Manolova, Francesca Vinchi

Blood (2022) 140 (Supplement 1): 5341–5342.

https://doi.org/10.1182/blood-2022-170164

Published: 2022

Journal Articles

Differential Recovery of Macrophage Iron Deficiency By Oral Iron Formulations Determines Cell Inflammatory Response in Conditions of Iron Deficiency Anemia

Ada Antypiuk, Richa Sharma, Elisa Brilli, Germano Tarantino, Francesca Vinchi

Blood (2022) 140 (Supplement 1): 5335–5336.

https://doi.org/10.1182/blood-2022-165292

Published: 2022

Journal Articles

Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism

Richa Sharma, S. Zebulon Vance, Ada Antypiuk, Deepa Manwani, Quentinn Pearce, James E. Cox, Xiuli An, Karina Yazdanbakhsh, Francesca Vinchi

Blood (2022) 140 (Supplement 1): 2456–2457.

https://doi.org/10.1182/blood-2022-165364

Published: 2022

NARROW

Combination Therapy with Luspatercept and the Ferroportin Inhibitor Vamifeport Is Superior to Either Drug Alone in Improving Anemia and Reducing Myeloid Skewing in MDS

Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model

Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease

Genetic Iron Overload Aggravates and Pharmacological Iron Restriction Improves MDS Pathophysiology in a Preclinical Mouse Model

Differential Recovery of Macrophage Iron Deficiency By Oral Iron Formulations Determines Cell Inflammatory Response in Conditions of Iron Deficiency Anemia

Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism

Email alerts

ASH Publications

American Society of Hematology

Combination Therapy with Luspatercept and the Ferroportin Inhibitor Vamifeport Is Superior to Either Drug Alone in Improving Anemia and Reducing Myeloid Skewing in MDS

Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model

Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease

Genetic Iron Overload Aggravates and Pharmacological Iron Restriction Improves MDS Pathophysiology in a Preclinical Mouse Model

Differential Recovery of Macrophage Iron Deficiency By Oral Iron Formulations Determines Cell Inflammatory Response in Conditions of Iron Deficiency Anemia

Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only